New study finds no clear evidence of benefits in ongoing debate about name-reporting of HIV infection

November 14, 1999

In one of the largest studies to date, a team of AIDS researchers concludes that name-based reporting programs for HIV infection are not producing specific public health benefits in the effort to control the AIDS epidemic. The study is the first multi-state, random survey to examine how HIV name-reporting affects public health interventions. It was conducted by a team from UC San Francisco, UC Berkeley, eight state health departments, and the Centers for Disease Control and Prevention.

The research results, published in the November 16 issue of Annals of Internal Medicine, present more data in the ongoing policy debate over the advantages and disadvantages of name-reporting of HIV infection. This reporting system is required by law in 31 states, but it remains controversial. All states require name-reporting of an AIDS diagnosis.

Name-reporting of HIV infection--which also is known as name-based HIV surveillance--requires that all adults who test positive for HIV be reported by name to a public health department unless the HIV test is done at a site that specifically offers anonymous HIV testing. Most states, including the majority with laws requiring HIV name- reporting, provide some sites where an anonymous HIV test can be obtained. In anonymous HIV testing, the result is linked to an identification number and not a person's name.

HIV name-reporting, according to some advocates, is beneficial because it sets up the potential for the health department to assist HIV-positive individuals in receiving timely medical treatment and in notifying their sex and needle-sharing partners about possible exposure to the AIDS virus. Opponents of HIV name-reporting have feared that the policy could be a deterrent to persons seeking care for HIV.

"We found both the positive and the negative ways that name-based surveillance programs supposedly affect public health interventions-specifically partner notification and access to health care-to be exaggerated. Our data showed no effect one way or the other. The findings do open up discussion as to whether public health funds spent on these interventions are being used in the most effective way," said Dennis Osmond, PhD, lead author of the Annals article and associate professor in the UCSF Department of Epidemiology and Biostatistics and UCSF Center for AIDS Prevention Studies (CAPS).

In understanding this subject, Osmond also noted that name-based HIV reporting should not be confused with name-based AIDS reporting. HIV reporting applies to persons who are undergoing testing to find out if they have HIV infection. AIDS reporting applies to HIV-positive persons who are newly diagnosed with the disease AIDS or its complications. This diagnosis, which is made by a health care provider, is always attached to an individual's name and is reported to a public health department in all 50 states.

The study involved close to 2,000 HIV-positive persons who were newly diagnosed with AIDS during 1995-96. At the time, participants came from five states that had name-based reporting policies (Arizona, Colorado, Mississippi, Missouri, North Carolina) and three that did not (Texas, Oregon, and New Mexico). New Mexico has since passed a name-based surveillance law.

Personal interviews took place with all study participants, and they self-reported their experience with HIV testing, getting into care for HIV, contact with the health department, and notification to at-risk sex and needle-sharing partners. The sample included men who had sex with men, persons who used injection drugs, and heterosexual persons randomly selected from newly reported AIDS cases in each state.

The main study findings include:"I expect that HIV name-reporting will remain controversial because it raises several sets of controversial issues, such as the potential effect of delaying or avoiding an HIV test, the value for monitoring the HIV/AIDS epidemic, and the value of public health interventions. However, separating the issues about surveillance itself from the issues about the use of surveillance to deliver the public health interventions that we evaluated would help focus the debate," Osmond said.

Arthur Reingold, MD, professor of epidemiology in the School of Public Health at UC Berkeley, was principal investigator of the study. Co-investigators were Andrew Bindman, MD; Karen Vranizan, MA; Frederick Hecht, MD, and Dennis Keane, MPH, of UCSF and San Francisco General Hospital Medical Center; and J. Stan Lehman, MPH, of CDC.

The study was funded by CDC as part of the Multistate Evaluation of Surveillance for HIV (MESH) project.
UCSF CAPS is part of the UCSF AIDS Research Institute, a campuswide enterprise without walls that encompasses all UCSF AIDS programs under a single umbrella and includes close to 1,000 investigators. Thomas J. Coates, PhD, is director of UCSF CAPS and executive director of UCSF ARI.

University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to